Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient

• US 10,214,743 B2
• Filed: 03/04/2015
• Issued: 02/26/2019
• Est. Priority Date: 03/04/2014
• Status: Active Grant

• Current Assignee: Hirofumi Yamamoto, Masaki Mori
• Original Assignee: Hirofumi Yamamoto, Masaki Mori
• Inventors: Yamamoto, Hirofumi, Mori, Masaki, Doki, Yuichiro, Nishimura, Junichi
• Primary Examiner(s): Hill, Kevin K
• Application Number:
  US15/123,621
• Publication Number:
  US 20170073686A1
• Time in Patent Office: 1,455 Days
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA

Abstract

The purpose of the present invention is to provide a colorectal cancer drug that uses microRNA exhibiting outstanding effectiveness in colorectal cancer patients, particularly colorectal cancer patients having a mutated KRAS gene. miR4689 and/or miR4685-3p can suppress the growth of colorectal cancer cells, particularly colorectal cancer cells having a mutated KRAS gene, and thus exhibit an effective antitumor effect.

Claims

1. A method of treating a colorectal cancer, comprising a step of administering a therapeutically effective amount of either one or both of miR4689 and miR4685-3p to a patient with the colorectal cancer.

2. The method according to claim 1, wherein the colorectal cancer is a KRAS-gene-mutant colorectal cancer.

3. The method according to claim 2, wherein the KRAS-gene-mutant colorectal cancer comprises a RAS gene having amino acid substitution at either one or both of a codon 12 and a codon 13.